Has Tecentriq earned a role in treatment of triple-negative breast cancer?

Here is what experts say

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Daniel HayesStuart B. Padnos Professor of Breast Cancer Research,University of Michigan Rogel Cancer Center

Because we have been siloed into tissue-of-origin treatment bins (melanoma, lung, colorectal, breast, etc) over the last 100 or more years, we have applied these therapies based more on where the cancer was derived than on the biology of the cancer itself.

Obviously, the field of immune-oncology has been one of the great success stories in our field over the last five years, based on our molecular understanding of the mechanisms of immune tolerance (or checkpoints) and how to disrupt that. Not only has ASCO declared Checkpoint Inhibition (as well as cellular-based immunotherapy) the “Advance of the Year,” the Nobel Committee awarded this year’s Prize to Drs. Allison and Honjo for their fabulous observations that led to these great breakthroughs.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

U.S. Deputy Secretary for Health and Human Services, Andrea Palm, and Sweden's Minister for Health Care, Acko Ankarberg Johansson, signing the agreement. Credit: Joel Apelthun/Government Offices of SwedenThe United States and Sweden signed an agreement to step up collaborations in science and technology by focusing on cancer research.

Login